top of page

FDA approves Genmab’s ofatumumab for relapsed CLL

The US Food and Drug Administration (FDA) has approved Genmab’s ofatumumab (Arzerra), in combination with fludarabine and cyclophosphamide (FC), to treat patients with relapsed chronic lymphocytic leukaemia (CLL).

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page